Replies to post #41499 on FLIGHT SCHOOL

[glassy]

INHX~11.02. some note worthy headlines IMO

Inhibitex market overreaction a buying opportunity, says Canaccord
Canaccord would be aggressive buyers of Inhibitex (INHX) due to the overreaction in shares following Pharmasset's (VRUS) PSI-938 clinical developments. The firm does not believe similarities between '938 and Inhibitex's INX-189 products should predict INX-189 longer term dosing toxicity profile. Share are Buy rated with a $22 price target. :theflyonthewall.com


http://www.theflyonthewall.com/permalinks/entry.php/INHXid1547100/INHX-Inhibitex-market-overreaction-a-buying-opportunity-says-Canaccord


Five Drug Stock Winners of 2011


http://www.thestreet.com/_yahoo/story/11349823/1/five-drug-stock-winners-of-2011.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA